The acaricidal efficacy of a novel oral formulation of afoxolaner (NEXGARD ® , Merial) against two European tick species was assessed in dogs experimentally infested with Ixodes ricinus and Dermacentor reticulatus. Three studies, each characterized by a negative controlled randomized block design, were conducted with a total of 52 beagle or mongrel dogs of both sexes. Starting 2 days before treatment, each dog was infested weekly with approximately 50 ticks. The number of live ticks was counted at 48 h post-treatment (Day 2) as well as 48 h following each infestation on Days 9, 16, 23, and 30. Afoxolaner, administered at an average dose of 2.7 mg/kg bodyweight (range 2.5-2.9 mg/kg), rapidly eliminated the pre-existing tick infestations with over 99% acaricidal efficacy and controlled the weekly re-infestations for up to 30 days post treatment with over 96% efficacy on both tick species. Afoxolaner provides excellent acaricidal efficacy against these two major European tick species using the oral route of administration.
Introduction
Ticks are endemic throughout Europe with more than twelve different species, which have varying biology and geographic distribution (Chomel, 2011) . Ixodes ricinus and Dermacentor reticulatus commonly infest dogs and are vectors of various canine vector borne pathogens including Borrelia burgdorferi and Anaplasma phagocytophilum, both transmitted by I. ricinus, and Babesia canis transmitted by D. reticulatus (Chomel, 2011; Dantas-Torres et al., 2012) . I. ricinus is found throughout Europe, except on the Mediterranean border, and D. reticulatus is widely distributed with areas of tick concentration dependent upon local environmental conditions (Beugnet and Chalvet-Monfray, 2013) .
The distribution of both tick species has been expanding in Europe as a result of climate change (Beugnet and Chalvet-Monfray, 2013; Daniel et al., 2003; Gray et al., 2009; Smith et al., 2011) . The period of tick activity also is increasing in Europe. For example, in Hungary the total duration of I. ricinus activity was shown to be 2 months longer in 2002 compared to the duration in 1950, and ticks were also found in winter, a finding not described in 1950 (Smith et al., 2011) . Similar findings are described for I. ricinus or D. reticulatus in Belgium, Switzerland, Poland, Germany, Slovenia and Slovakia (Bullova et al., 2009; Chomel, 2011; Reis et al., 2011; Siroky et al., 2011) by Dantas-Torres and Otranto (2013) , who showed that I. ricinus is present in southern Italy where it remains active throughout the year with spatiotemporal distribution patterns that are distinct from central and north European populations. The expansion of the geographic and temporal incidence of ticks throughout Europe and the increased movement of people and their companion animals between countries strengthen the need for effective tick control measures for dogs year-round (Otranto et al., 2009a,b) . The present study describes the results of three experimental studies that assessed the efficacy of afoxolaner, a new insecticide-acaricide administered orally in a soft chewable formulation (Nexgard ® , Merial), against I. ricinus and D. reticulatus in dogs. This new acaricide was tested for its curative property (i.e., its ability to kill ticks when administered to an infested dog), and for its prophylactic properties (i.e., its ability to prevent tick re-infestations for 30 days after treatment).
Materials and methods
Fifty-two dogs were included in three laboratory studies. Each study included 16-20 beagle or mongrel dogs of both sexes using a negative controlled randomized block design (Table 1) . All dogs were healthy, >6 months of age, between 7.9 and 18.4 kg bodyweight at inclusion, and no dogs had been infested by ticks nor treated with any insecticidal-acaricidal drug in a 3-month period before inclusion.
The health condition of all dogs was monitored at least once daily and additionally once per hour during the first four h post treatment. They were acclimated to the study conditions for at least 7 days prior to treatment. All dogs had free access to water and were fed a commercial diet provided in an amount and manner that supplied nutrient and energy requirements to ensure their health and well-being. All animal procedures in this study were reviewed and approved by the Merial Ethics Committee (USDA, 2008) . The study design was in accordance with the World Association for the Advancement of Veterinary Parasitology (WAAVP) guidelines for evaluating the efficacy of parasiticides for the treatment, prevention and control of flea and tick infestation on dogs and cats (Marchiondo et al., 2013) , and was conducted in accordance with Good Clinical Practices as described in International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) guideline GL9 (EMEA, 2000) .
In each of the 3 studies, two groups of equal size were randomly formed based on decreasing pre-treatment tick counts (performed during acclimation, 48 h after infestation). Dogs were either untreated or treated once orally with the appropriate combination of soft chews containing afoxolaner (day of treatment was Day 0). Four sizes of chews were available: 0.5 g, 1.25 g, 3 g and 6 g, containing respectively 11.3 mg, 28.3 mg, 68 mg and 136 mg of afoxolaner. As the soft chews cannot be cut, the dosing was administered by giving one or more of the chews to be as close as possible to the minimum effective dose of 2.5 mg/kg, resulting in an average dose of 2.7 mg/kg of afoxolaner per each treated group (Table 1) . Dogs were fasted overnight prior to treatment and fed approximately four h after treatment in Study A but were fed in the hour before treatment in Studies B and C.
On Days −2, 7, 14, 21 and 28, all dogs were infested with 50 unfed adult ticks (with approximately equal sex ratio for D. reticulatus in Studies A and B, and 50 females of I. ricinus, with 10 additional males to stimulate attachment, in Study C). Ticks were from laboratory-maintained populations that had been established from ticks collected in field locations in Europe. Live ticks were counted and removed 48 h after treatment or infestations on Days 2, 9, 16, 23, and 30. These counts consisted of the methodical examination of all body areas using finger tips and/or a coarse tooth comb to sort through the hair and locate all ticks on the animal, as described by Marchiondo et al. (2013) . All personnel conducting tick counts and health observations were blinded to treatment groups.
For each tick count, including male and female ticks, the total count of live adult ticks was transformed to the natural logarithm of (count + 1) to calculate the geometric mean for each treatment group. The percent reduction of the tick counts from treated dogs compared to those from untreated dogs (= percentage efficacy) was calculated using the formula [(C − T)/C] × 100, where C is the geometric mean for the control group and T is the geometric mean for the treated group at the same time point. The tick counts of the treated and untreated groups were also compared using Friedman's test. All testing was two-sided at the significance level p = 0.05.
For each study, the therapeutic efficacy of afoxolaner against Day −2 infestation and the efficacy of afoxolaner in the prevention of weekly tick re-infestations starting on Day 7 after treatment were assessed.
Results
In the control groups, the geometric mean of live ticks counted at each time point was between 19.9 and 32.3 for infestations with D. reticulatus and between 23.4 and 34.2 for I. ricinus (Table 2) . To allow the comparison between control and treated groups, the minimum retention rate of ticks should be at least 20% (i.e., 10 ticks for an a 50 unfed ticks of equal sex ratio were used for infestation with D. reticulatus. 50 unfed female ticks with approximately 10 males were used for infestation with I. ricinus. infestation with 50) in order to make a valid assessment of tick efficacy (Marchiondo et al., 2013) . The control dogs were adequately infested in the 3 studies.
In the treated groups, the tick reduction was significant (p < 0.002) compared to the control groups for each time point of each study (Table 3) . Afoxolaner treatment provided a complete elimination of all ticks when infestation existed prior to treatment (therapeutic efficacy) and provided over 96.4% acaricidal efficacy against D. reticulatus and over 99.6% against I. ricinus up to Day 30 (Table 3) when infestations occurred after treatment (prophylactic efficacy). No adverse effects related to treatment were observed.
Discussion
A single oral treatment with the chewable formulation of afoxolaner achieved 100% therapeutic efficacy for treating pre-existing infestations by I. ricinus and D. reticulatus. It also controlled re-infestations of ticks within 48 h for 4 weeks after treatment as demonstrated by the prophylactic efficacy, which was over 96.4% for the 2 studies against D. reticulatus and over 99.6% for the I. ricinus study. No difference was observed in efficacy against D. reticulatus ticks between fasted (Study A) and fed (Study B) dogs. Treated dogs in all three studies accepted the afoxolaner chews without adverse reactions, based on hourly post-treatment observations and daily observations.
The acaricidal efficacy of afoxolaner against I. ricinus and D. reticulatus observed in these studies was similar to what is usually observed with topical products. For example, against I. ricinus, two spot-on solutions, one with pyriprole and one with permethrin/imidacloprid provided a curative efficacy of 100% and 67.0%, respectively on Day 2, and greater than 98.7% prophylactic efficacy up to 30 days when assessed 48 h after tick infestations (Epe et al., 2003; Schuele et al., 2008) . In a study comparing three topical treatments against D. reticulatus (Tielemans et al., 2010) , the efficacies were 100%, 76% and 70% on Day 30 for fipronil/(S)-methoprene, permethrin/imidacloprid and metaflumizone/amitraz, respectively. The oral formulation of afoxolaner is the first one to provide an efficacy against tick for a month, as it is described for topical products. Nevertheless, no direct comparison is available.
The systemic distribution of the tested product offer advantages compared to the topical formulations. One benefit is the lower possibility of exposure of the owner during the time necessary for a topical product to be absorbed through the skin of a treated dog. Another significant advantage of an orally administered, systemically active product is that rainy conditions, shampooing, or other concurrent topical treatments will not interfere with the efficacy (Beugnet and Franc, 2012) .
In conclusion, the chewable formulation containing the new insecticide-acaricide afoxolaner is a convenient and efficacious ectoparasiticide treatment for dogs that treats and prevents tick infestations for up to 1 month.
